Adalimumab (CLASSIC & CHARM trial - Crohn) | Digestive Disease Dashboard
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial - ScienceDirect
The Efficacy of Anti-TNFs in Immune-Mediated Disease - European Medical Journal
HUMIRA® (adalimumab) for Crohn's Disease in adults
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial - ScienceDirect
![PDF] Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/65eacb27ce81f30a0f2e7ef0d05e54a6f0bc0091/5-Figure2-1.png "PDF] Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. | Semantic Scholar")
PDF] Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. | Semantic Scholar
![PDF] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e0cae5bfe02af6c86528d27d0b3501b3d52ce4ae/6-Figure2-1.png "PDF] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. | Semantic Scholar")
PDF] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. | Semantic Scholar
Refining the Role of TNF Antagonists for Crohn's Disease
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial - The Lancet
SciELO - Brasil - ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN'S DISEASE: results of a Latin American single-center observational study ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN'S DISEASE:
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Design of the included studies of adalimumab for Crohn?s disease (CD).... | Download Scientific Diagram
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study
Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study | Gastroenterología y Hepatología (English Edition)
IJMS | Free Full-Text | A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study | Gastroenterología y Hepatología (English Edition)
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Effi cacy of adalimumab (ADA) as a maintenance therapy for Crohn's... | Download Scientific Diagram
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial - ScienceDirect
